Search company, investor...

Onepharm Research and Development

onepharm.com

Founded Year

2005

Stage

Other Investors | Alive

About Onepharm Research and Development

Onepharm Research and Development offers a product isolated from a medicinal plant, with anti-inflammatory activity

Headquarters Location

Gersthofer Straße 29-31

1180,

Austria

Missing: Onepharm Research and Development's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Onepharm Research and Development's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Onepharm Research and Development Frequently Asked Questions (FAQ)

  • When was Onepharm Research and Development founded?

    Onepharm Research and Development was founded in 2005.

  • What is Onepharm Research and Development's latest funding round?

    Onepharm Research and Development's latest funding round is Other Investors.

  • Who are the investors of Onepharm Research and Development?

    Investors of Onepharm Research and Development include Osterreichische Forschungsforderungsgesellschaft and Austria Wirtschaftsservice.

  • Who are Onepharm Research and Development's competitors?

    Competitors of Onepharm Research and Development include Zosano Pharma, Vaccinex, Itaconix, Amira Pharmaceuticals, D-Pharm and 11 more.

Compare Onepharm Research and Development to Competitors

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

S
SunTen Phytotech

SunTen Phytotech (STPT) develops botanical medicines and functional dietary products with proven efficacy and safety, constructs advanced technical platforms for new botanical drug research and development, and aims to provide CMC services of botanical products. SunTen also aims to provide high quality services in developing bio-medical products.

A
Appian International Research

Appian aims to provide consulting and operational support in pharmaceutical product development. The company grew out of the contract pharmaceutical research industry. Dr. Grier Harris, Appian's President, has worked in clinical trials since 1986 in most areas within the industry - from basic medical research to large scale international clinical trials.

C
Choice Research of Birmingham

Choice Research of Birmingham is a company that manages clinical development trials.

I
Intas Pharmaceuticals

Intas Pharmaceuticals is a provider of pharmaceutical services. It specializes in pharmaceutical formulation development, manufacturing, and marketing. The firm serves clients in the healthcare sector. It was founded in 1977 and is based in Ahmedabad, India.

M
Marksans Pharma

Marksans Pharma (formerly Glenmark Laboratories) is one of the pharmaceuticals company in India, with a focused approach on creating a world class, global, pharmaceutical company. Its manufacturing plant is an in Asia and is approved by UK-MCHRA and Australian-TGA authorities. Marksans' focus is to become a preferred supplier for formulation outsourcing by first world countries, develop a marketing presence in the EU and, through a combination of licensing and partnering, become a integrated pharmaceutical company. It has just completed the reverse takeover of TASC Pharmaceuticals, a publicly quoted API company, to form a corporation valued at $120 million.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.